| Interaction |
Description |
|
alprazolam -
erythromycin
|
The macrolide increases the effect of the benzodiazepine
(source: Drug Bank
)
|
|
alprazolam -
erythromycin
|
The macrolide increases the effect of the benzodiazepine
(source: Drug Bank
)
|
|
alprazolam -
erythromycin
|
The macrolide increases the effect of the benzodiazepine
(source: Drug Bank
)
|
|
aminophylline -
erythromycin
|
The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, aminophylline.
(source: Drug Bank
)
|
|
amiodarone -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
amiodarone -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
aprepitant -
erythromycin
|
The CYP3A4 inhibitor increases the effect and toxicity of aprepitant
(source: Drug Bank
)
|
|
astemizole -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
astemizole -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
atorvastatin -
erythromycin
|
The macrolide possibly increases the statin toxicity
(source: Drug Bank
)
|
|
atorvastatin -
erythromycin
|
The macrolide, erythromycin, may increase the toxicity of the statin, atorvastatin.
(source: Drug Bank
)
|
|
bromazepam -
erythromycin
|
Erythromcyin may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if erythromycin is initiated, discontinued or dose changed. Dosage adjustments may be required.
(source: Drug Bank
)
|
|
bromocriptine -
erythromycin
|
Erythromycin increases serum levels of bromocriptine
(source: Drug Bank
)
|
|
bromocriptine -
erythromycin
|
Erythromycin increases serum levels of bromocriptine
(source: Drug Bank
)
|
|
buspirone -
erythromycin
|
The macrolide increases the effect and toxicity of buspirone
(source: Drug Bank
)
|
|
buspirone -
erythromycin
|
The macrolide, erythromycin, may increase the effect and toxicity of buspirone.
(source: Drug Bank
)
|
|
cabergoline -
erythromycin
|
Erythromycin increases serum levels and toxicity of cabergoline
(source: Drug Bank
)
|
|
cabergoline -
erythromycin
|
Erythromycin increases serum levels and toxicity of cabergoline
(source: Drug Bank
)
|
|
carbamazepine -
erythromycin
|
The macrolide increases the effect of carbamazepine
(source: Drug Bank
)
|
|
carbamazepine -
erythromycin
|
The macrolide, erythromycin, may increase the effect of carbamazepine.
(source: Drug Bank
)
|
|
cerivastatin -
erythromycin
|
The macrolide possibly increases the statin toxicity
(source: Drug Bank
)
|
|
cerivastatin -
erythromycin
|
The macrolide, erythromycin, may increase the toxicity of the statin, cerivastatin.
(source: Drug Bank
)
|
|
cilostazol -
erythromycin
|
Erythromycin increases the effect of cilostazol
(source: Drug Bank
)
|
|
cinacalcet -
erythromycin
|
The macrolide, erythromycin, may increase the serum concentration and toxicity of cinacalcet.
(source: Drug Bank
)
|
|
cisapride -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
cisapride -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
clozapine -
erythromycin
|
Erythromycin increases the effect of clozapine
(source: Drug Bank
)
|
|
clozapine -
erythromycin
|
Erythromycin increases the effect of clozapine
(source: Drug Bank
)
|
|
colchicine -
erythromycin
|
Severe colchicine toxicity can occur
(source: Drug Bank
)
|
|
colchicine -
erythromycin
|
Severe colchicine toxicity can occur
(source: Drug Bank
)
|
|
cyclosporine -
erythromycin
|
The macrolide increases the effect of cyclosporine
(source: Drug Bank
)
|
|
cyclosporine -
erythromycin
|
The macrolide, erythromycin, may increase the effect of cyclosporine.
(source: Drug Bank
)
|
|
diazepam -
erythromycin
|
The macrolide increases the effect of the benzodiazepine
(source: Drug Bank
)
|
|
diazepam -
erythromycin
|
The macrolide increases the effect of the benzodiazepine
(source: Drug Bank
)
|
|
digoxin -
erythromycin
|
The macrolide increases the effect of digoxin in 10% of patients
(source: Drug Bank
)
|
|
digoxin -
erythromycin
|
The macrolide, erythromycin, may increase the effect of digoxin in 10% of patients.
(source: Drug Bank
)
|
|
dihydroergotamine -
erythromycin
|
Possible ergotism and severe ischemia with this combination
(source: Drug Bank
)
|
|
dihydroergotamine -
erythromycin
|
Possible ergotism and severe ischemia with this combination
(source: Drug Bank
)
|
|
disopyramide -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
disopyramide -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
divalproex sodium -
erythromycin
|
Erythromycin increases the effect of valproic acid
(source: Drug Bank
)
|
|
docetaxel -
erythromycin
|
The agent increases the serum levels and toxicity of docetaxel
(source: Drug Bank
)
|
|
docetaxel -
erythromycin
|
Erythromycin may increase the serum levels and toxicity of docetaxel.
(source: Drug Bank
)
|
|
eletriptan -
erythromycin
|
This macrolide increases the effect and toxicity of eletriptan
(source: Drug Bank
)
|
|
eletriptan -
erythromycin
|
The macrolide, erythromycin, may increase the effect and toxicity of eletriptan.
(source: Drug Bank
)
|
|
eplerenone -
erythromycin
|
This CYP3A4 inhibitor increases the effect and toxicity of eplerenone
(source: Drug Bank
)
|
|
ergotamine -
erythromycin
|
Possible ergotism and severe ischemia with this combination
(source: Drug Bank
)
|
|
ergotamine -
erythromycin
|
Possible ergotism and severe ischemia with this combination
(source: Drug Bank
)
|
|
erythromycin -
acenocoumarol
|
The macrolide increases anticoagulant effect
(source: Drug Bank
)
|
|
erythromycin -
acenocoumarol
|
The macrolide, erythromycin, may increase the anticoagulant effect of acenocoumarol.
(source: Drug Bank
)
|
|
erythromycin -
alfentanil
|
The macrolide increases the effect and toxicity of alfentanil
(source: Drug Bank
)
|
|
erythromycin -
alfentanil
|
The macrolide, erythromycin, may increase the effect and toxicity of alfentanil.
(source: Drug Bank
)
|
|
erythromycin -
alprazolam
|
The macrolide increases the effect of the benzodiazepine
(source: Drug Bank
)
|
|
erythromycin -
alprazolam
|
The macrolide increases the effect of the benzodiazepine
(source: Drug Bank
)
|
|
erythromycin -
aminophylline
|
The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, aminophylline.
(source: Drug Bank
)
|
|
erythromycin -
amiodarone
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
amiodarone
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
anisindione
|
The macrolide, erythromycin, may increase the anticoagulant effect of anisindione.
(source: Drug Bank
)
|
|
erythromycin -
aprepitant
|
This CYP3A4 inhibitor increases effect and toxicity of aprepitant
(source: Drug Bank
)
|
|
erythromycin -
astemizole
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
astemizole
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
atorvastatin
|
The macrolide possibly increases the statin toxicity
(source: Drug Bank
)
|
|
erythromycin -
atorvastatin
|
The macrolide, erythromycin, may increase the toxicity of the statin, atorvastatin.
(source: Drug Bank
)
|
|
erythromycin -
bretylium
|
Increased risk of cardiotoxicity and arryhthmias
(source: Drug Bank
)
|
|
erythromycin -
bretylium
|
Increased risk of cardiotoxicity and arryhthmias
(source: Drug Bank
)
|
|
erythromycin -
bromocriptine
|
Erythromycin increases serum levels of bromocriptine
(source: Drug Bank
)
|
|
erythromycin -
bromocriptine
|
Erythromycin increases serum levels of bromocriptine
(source: Drug Bank
)
|
|
erythromycin -
buspirone
|
The macrolide increases the effect and toxicity of buspirone
(source: Drug Bank
)
|
|
erythromycin -
buspirone
|
The macrolide, erythromycin, may increase the effect and toxicity of buspirone.
(source: Drug Bank
)
|
|
erythromycin -
cabergoline
|
Erythromycin increases serum levels and toxicity of cabergoline
(source: Drug Bank
)
|
|
erythromycin -
cabergoline
|
Erythromycin increases serum levels and toxicity of cabergoline
(source: Drug Bank
)
|
|
erythromycin -
carbamazepine
|
The macrolide increases the effect of carbamazepine
(source: Drug Bank
)
|
|
erythromycin -
carbamazepine
|
The macrolide, erythromycin, may increase the effect of carbamazepine.
(source: Drug Bank
)
|
|
erythromycin -
cerivastatin
|
The macrolide possibly increases the statin toxicity
(source: Drug Bank
)
|
|
erythromycin -
cerivastatin
|
The macrolide, erythromycin, may increase the toxicity of the statin, cerivastatin.
(source: Drug Bank
)
|
|
erythromycin -
cilostazol
|
Erythromycin increases the effect of cilostazol
(source: Drug Bank
)
|
|
erythromycin -
cinacalcet
|
The macrolide, erythromycin, may increase the serum concentration and toxicity of cinacalcet.
(source: Drug Bank
)
|
|
erythromycin -
cisapride
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
cisapride
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
citalopram
|
Possible serotoninergic syndrome with this combination
(source: Drug Bank
)
|
|
erythromycin -
citalopram
|
Possible serotoninergic syndrome with this combination
(source: Drug Bank
)
|
|
erythromycin -
clozapine
|
Erythromycin increases the effect of clozapine
(source: Drug Bank
)
|
|
erythromycin -
clozapine
|
Erythromycin increases the effect of clozapine
(source: Drug Bank
)
|
|
erythromycin -
colchicine
|
Severe colchicine toxicity can occur
(source: Drug Bank
)
|
|
erythromycin -
colchicine
|
Severe colchicine toxicity can occur
(source: Drug Bank
)
|
|
erythromycin -
cyclosporine
|
The macrolide increases the effect of cyclosporine
(source: Drug Bank
)
|
|
erythromycin -
cyclosporine
|
The macrolide, erythromycin, may increase the effect of cyclosporine.
(source: Drug Bank
)
|
|
erythromycin -
diazepam
|
The macrolide increases the effect of the benzodiazepine
(source: Drug Bank
)
|
|
erythromycin -
diazepam
|
The macrolide increases the effect of the benzodiazepine
(source: Drug Bank
)
|
|
erythromycin -
dicumarol
|
The macrolide increases anticoagulant effect
(source: Drug Bank
)
|
|
erythromycin -
dicumarol
|
The macrolide, erythromycin, may increase the anticoagulant effect of dicumarol..
(source: Drug Bank
)
|
|
erythromycin -
digoxin
|
The macrolide increases the effect of digoxin in 10% of patients
(source: Drug Bank
)
|
|
erythromycin -
digoxin
|
The macrolide, erythromycin, may increase the effect of digoxin in 10% of patients.
(source: Drug Bank
)
|
|
erythromycin -
dihydroergotamine
|
Possible ergotism and severe ischemia with this combination
(source: Drug Bank
)
|
|
erythromycin -
dihydroergotoxine
|
Possible ergotism and severe ischemia with this combination
(source: Drug Bank
)
|
|
erythromycin -
disopyramide
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
disopyramide
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
docetaxel
|
The agent increases the serum levels and toxicity of docetaxel
(source: Drug Bank
)
|
|
erythromycin -
docetaxel
|
Erythromycin may increase the serum levels and toxicity of docetaxel.
(source: Drug Bank
)
|
|
erythromycin -
dofetilide
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
dofetilide
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
dyphylline
|
The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, dyphylline.
(source: Drug Bank
)
|
|
erythromycin -
eletriptan
|
The macrolide increases the effect and toxicity of eletriptan
(source: Drug Bank
)
|
|
erythromycin -
eletriptan
|
The macrolide, erythromycin, may increase the effect and toxicity of eletriptan.
(source: Drug Bank
)
|
|
erythromycin -
eplerenone
|
This CYP3A4 inhibitor increases the effect and toxicity of eplerenone
(source: Drug Bank
)
|
|
erythromycin -
ergonovine
|
Possible ergotism and severe ischemia with this combination
(source: Drug Bank
)
|
|
erythromycin -
ergonovine
|
Possible ergotism and severe ischemia with this combination
(source: Drug Bank
)
|
|
erythromycin -
ergotamine
|
Possible ergotism and severe ischemia with this combination
(source: Drug Bank
)
|
|
erythromycin -
erlotinib
|
This CYP3A4 inhibitor increases levels/toxicity of erlotinib
(source: Drug Bank
)
|
|
erythromycin -
erlotinib
|
This CYP3A4 inhibitor increases levels/toxicity of erlotinib
(source: Drug Bank
)
|
|
erythromycin -
everolimus
|
The macrolide, erythromycin, may increase the serum concentration and toxicity of everolimus.
(source: Drug Bank
)
|
|
erythromycin -
felodipine
|
Erythromycin increases the effect of felodipine
(source: Drug Bank
)
|
|
erythromycin -
felodipine
|
Erythromycin increases the effect of felodipine
(source: Drug Bank
)
|
|
erythromycin -
fluoxetine
|
Possible serotoninergic syndrome with this combination
(source: Drug Bank
)
|
|
erythromycin -
fluoxetine
|
Possible serotoninergic syndrome with this combination
(source: Drug Bank
)
|
|
erythromycin -
gefitinib
|
This CYP3A4 inhibitor increases levels/toxicity of gefitinib
(source: Drug Bank
)
|
|
erythromycin -
gefitinib
|
This CYP3A4 inhibitor increases levels/toxicity of gefitinib
(source: Drug Bank
)
|
|
erythromycin -
grepafloxacin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
grepafloxacin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
imatinib
|
The macrolide increases levels of imatinib
(source: Drug Bank
)
|
|
erythromycin -
imatinib
|
The macrolide, erythromycin, may increase the serum concentration of imatinib.
(source: Drug Bank
)
|
|
erythromycin -
itraconazole
|
The macrolide increases the effect and toxicity of itraconazole
(source: Drug Bank
)
|
|
erythromycin -
itraconazole
|
The macrolide, erythromycin, may increase the effect and toxicity of itraconazole.
(source: Drug Bank
)
|
|
erythromycin -
levofloxacin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
levofloxacin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
lincomycin
|
Possible antagonism of action with this combination
(source: Drug Bank
)
|
|
erythromycin -
lovastatin
|
The macrolide possibly increases the statin toxicity
(source: Drug Bank
)
|
|
erythromycin -
lovastatin
|
The macrolide, erythromycin, may increase the toxicity of the statin, lovastatin.
(source: Drug Bank
)
|
|
erythromycin -
mesoridazine
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
mesoridazine
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
methylergonovine
|
Possible ergotism and severe ischemia with this combination
(source: Drug Bank
)
|
|
erythromycin -
methylergonovine
|
Possible ergotism and severe ischemia with this combination
(source: Drug Bank
)
|
|
erythromycin -
methylprednisolone
|
The macrolide increases the effect of corticosteroid
(source: Drug Bank
)
|
|
erythromycin -
methylprednisolone
|
The macrolide, erythromycin, may increase the effect of corticosteroid, methylprednisolone.
(source: Drug Bank
)
|
|
erythromycin -
methysergide
|
Possible ergotism and severe ischemia with this combination
(source: Drug Bank
)
|
|
erythromycin -
midazolam
|
The macrolide increases the efect of the benzodiazepine
(source: Drug Bank
)
|
|
erythromycin -
midazolam
|
The macrolide increases the efect of the benzodiazepine
(source: Drug Bank
)
|
|
erythromycin -
moxifloxacin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
moxifloxacin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
oxtriphylline
|
The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline.
(source: Drug Bank
)
|
|
erythromycin -
pimozide
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
pimozide
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
quetiapine
|
This macrolide increases the effect/toxicity of quetiapine
(source: Drug Bank
)
|
|
erythromycin -
quetiapine
|
The macrolide, erythromycin, may increase the effect and toxicity of quetiapine.
(source: Drug Bank
)
|
|
erythromycin -
quinidine
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
quinidine
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
quinupristin
|
This combination presents an increased risk of toxicity
(source: Drug Bank
)
|
|
erythromycin -
ranolazine
|
Increased levels of ranolazine - risk of toxicity
(source: Drug Bank
)
|
|
erythromycin -
repaglinide
|
This macrolide increases effect of repaglinide
(source: Drug Bank
)
|
|
erythromycin -
repaglinide
|
The macrolide, erythromycin, may increase effect of repaglinide.
(source: Drug Bank
)
|
|
erythromycin -
rifabutin
|
The rifamycin decreases the effect of the macrolide
(source: Drug Bank
)
|
|
erythromycin -
rifabutin
|
The rifamycin, rifabutin, may decrease the effect of the macrolide, erythromycin.
(source: Drug Bank
)
|
|
erythromycin -
rifampin
|
The rifamycin decreases the effect of the macrolide
(source: Drug Bank
)
|
|
erythromycin -
rifampin
|
The rifamycin, rifampin, may decrease the effect of the macrolide, erythromycin.
(source: Drug Bank
)
|
|
erythromycin -
ritonavir
|
Increased toxicity of both agents
(source: Drug Bank
)
|
|
erythromycin -
ritonavir
|
Increased toxicity of both agents
(source: Drug Bank
)
|
|
erythromycin -
sertraline
|
Possible serotoninergic syndrome with this combination
(source: Drug Bank
)
|
|
erythromycin -
sertraline
|
Possible serotoninergic syndrome with this combination
(source: Drug Bank
)
|
|
erythromycin -
sibutramine
|
Erythromycin increases the effect and toxicity of sibutramine
(source: Drug Bank
)
|
|
erythromycin -
sibutramine
|
Erythromycin increases the effect and toxicity of sibutramine
(source: Drug Bank
)
|
|
erythromycin -
sildenafil
|
The macrolide increases the effect and toxicity of sildenafil
(source: Drug Bank
)
|
|
erythromycin -
sildenafil
|
The macrolide, erythromycin, may increase the effect and toxicity of sildenafil.
(source: Drug Bank
)
|
|
erythromycin -
simvastatin
|
The macrolide possibly increases the statin toxicity
(source: Drug Bank
)
|
|
erythromycin -
simvastatin
|
The macrolide, erythromycin, may increase the toxicity of the statin, simvastatin.
(source: Drug Bank
)
|
|
erythromycin -
sirolimus
|
The macrolide increases sirolimus levels
(source: Drug Bank
)
|
|
erythromycin -
sirolimus
|
The macrolide, erythromycin, may increase the serum concentration of sirolimus.
(source: Drug Bank
)
|
|
erythromycin -
sodium
|
Erythromycin increases the effect of valproic acid
(source: Drug Bank
)
|
|
erythromycin -
sotalol
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
sotalol
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
sparfloxacin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
sparfloxacin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
tacrolimus
|
Erythromycin increases the effect and toxicity of tacrolimus
(source: Drug Bank
)
|
|
erythromycin -
tacrolimus
|
Erythromycin increases the effect and toxicity of tacrolimus
(source: Drug Bank
)
|
|
erythromycin -
terfenadine
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
terfenadine
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
theophylline
|
The macrolide increases the effect and toxicity of theophylline
(source: Drug Bank
)
|
|
erythromycin -
theophylline
|
The macrolide, erythromycin, may increase the effect and toxicity of theophylline.
(source: Drug Bank
)
|
|
erythromycin -
thioridazine
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
thioridazine
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
triazolam
|
The macrolide increases the effect of the benzodiazepine
(source: Drug Bank
)
|
|
erythromycin -
triazolam
|
The macrolide increases the effect of the benzodiazepine
(source: Drug Bank
)
|
|
erythromycin -
vardenafil
|
The macrolide increases the effect and toxicity of vardenafil
(source: Drug Bank
)
|
|
erythromycin -
vardenafil
|
The macrolide, erythromycin, may increase the effect and toxicity of vardenafil.
(source: Drug Bank
)
|
|
erythromycin -
verapamil
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
verapamil
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
erythromycin -
vinblastine
|
Erythromycin increases vinblastine toxicity
(source: Drug Bank
)
|
|
erythromycin -
vinblastine
|
Erythromycin increases vinblastine toxicity
(source: Drug Bank
)
|
|
erythromycin -
warfarin
|
The macrolide increases anticoagulant effect
(source: Drug Bank
)
|
|
erythromycin -
warfarin
|
The macrolide, erythromycin, may increase the anticoagulant effect of warfarin.
(source: Drug Bank
)
|
|
erythromycin -
zafirlukast
|
Erythromycin decreases the effect of zafirlukast
(source: Drug Bank
)
|
|
erythromycin -
zafirlukast
|
Erythromycin decreases the effect of zafirlukast
(source: Drug Bank
)
|
|
felodipine -
erythromycin
|
Erythromycin increases the effect of felodipine
(source: Drug Bank
)
|
|
felodipine -
erythromycin
|
Erythromycin increases the effect of felodipine
(source: Drug Bank
)
|
|
fluoxetine -
erythromycin
|
Possible serotoninergic syndrome with this combination
(source: Drug Bank
)
|
|
fluoxetine -
erythromycin
|
Possible serotoninergic syndrome with this combination
(source: Drug Bank
)
|
|
gefitinib -
erythromycin
|
This CYP3A4 inhibitor increases levels/toxicity of gefitinib
(source: Drug Bank
)
|
|
gefitinib -
erythromycin
|
This CYP3A4 inhibitor increases levels/toxicity of gefitinib
(source: Drug Bank
)
|
|
grepafloxacin -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
grepafloxacin -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
imatinib -
erythromycin
|
The macrolide increases levels of imatinib
(source: Drug Bank
)
|
|
imatinib -
erythromycin
|
The macrolide, erythromycin, may increase the serum concentration of imatinib.
(source: Drug Bank
)
|
|
itraconazole -
erythromycin
|
The macrolide increases the effect and toxicity of itraconazole
(source: Drug Bank
)
|
|
itraconazole -
erythromycin
|
The macrolide, erythromycin, may increase the effect and toxicity of itraconazole.
(source: Drug Bank
)
|
|
levofloxacin -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
levofloxacin -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
lincomycin -
erythromycin
|
Possible antagonism of action
(source: Drug Bank
)
|
|
lovastatin -
erythromycin
|
The macrolide possibly increases the statin toxicity
(source: Drug Bank
)
|
|
lovastatin -
erythromycin
|
The macrolide, erythromycin, may increase the toxicity of the statin, lovastatin.
(source: Drug Bank
)
|
|
mesoridazine -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
mesoridazine -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
methysergide -
erythromycin
|
Possible ergotism and severe ischemia with this combination
(source: Drug Bank
)
|
|
methysergide -
erythromycin
|
Possible ergotism and severe ischemia with this combination
(source: Drug Bank
)
|
|
midazolam -
erythromycin
|
The macrolide increases the effect of benzodiazepine
(source: Drug Bank
)
|
|
midazolam -
erythromycin
|
The macrolide increases the effect of benzodiazepine
(source: Drug Bank
)
|
|
moxifloxacin -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
moxifloxacin -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
oxtriphylline -
erythromycin
|
The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline.
(source: Drug Bank
)
|
|
pimozide -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
pimozide -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
quetiapine -
erythromycin
|
This macrolide increases the effect/toxicity of quetiapine
(source: Drug Bank
)
|
|
quetiapine -
erythromycin
|
The macrolide, erythromycin, may increase the effect and toxicity of quetiapine.
(source: Drug Bank
)
|
|
quinidine -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
quinidine -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
quinupristin -
erythromycin
|
This combination presents an increased risk of toxicity
(source: Drug Bank
)
|
|
ranolazine -
erythromycin
|
Increased levels of ranolazine - risk of toxicity
(source: Drug Bank
)
|
|
repaglinide -
erythromycin
|
The macrolide increases the effect of repaglinide
(source: Drug Bank
)
|
|
repaglinide -
erythromycin
|
The macrolide, erythromycin, may increase the effect of repaglinide.
(source: Drug Bank
)
|
|
rifabutin -
erythromycin
|
The rifamycin decreases the effect of the macrolide
(source: Drug Bank
)
|
|
rifabutin -
erythromycin
|
The rifamycin, rifabutin, may decrease the effect of the macrolide, erythromycin.
(source: Drug Bank
)
|
|
rifampin -
erythromycin
|
The rifamycin decreases the effect of the macrolide
(source: Drug Bank
)
|
|
rifampin -
erythromycin
|
The rifamycin, rifampin, may decrease the effect of the macrolide, erythromycin.
(source: Drug Bank
)
|
|
tamsulosin -
erythromycin
|
Erythromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Erythromycin is initiated, discontinued, or dose changed.
(source: Drug Bank
)
|
|
tamsulosin -
erythromycin
|
Erythromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Erythromycin is initiated, discontinued, or dose changed.
(source: Drug Bank
)
|
|
telithromycin -
erythromycin
|
Telithromycin may reduce clearance of Erythromycin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Erythromycin if Telithromycin is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
terfenadine -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
terfenadine -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
theophylline -
erythromycin
|
The macrolide increases the effect and toxicity of theophylline
(source: Drug Bank
)
|
|
theophylline -
erythromycin
|
The macrolide, erythromycin, may increase the effect and toxicity of theophylline.
(source: Drug Bank
)
|
|
thioridazine -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
thioridazine -
erythromycin
|
Increased risk of cardiotoxicity and arrhythmias
(source: Drug Bank
)
|
|
thiothixene -
erythromycin
|
May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
(source: Drug Bank
)
|
|
thiothixene -
erythromycin
|
May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
(source: Drug Bank
)
|
|
topotecan -
erythromycin
|
The p-glycoprotein inhibitor, Erythromycin, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
(source: Drug Bank
)
|
|
toremifene -
erythromycin
|
Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
(source: Drug Bank
)
|
|
tramadol -
erythromycin
|
Erythromycin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
(source: Drug Bank
)
|
|
trazodone -
erythromycin
|
The CYP3A4 inhibitor, Erythromycin , may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Erythromycin is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
trazodone -
erythromycin
|
The CYP3A4 inhibitor, Erythromycin , may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Erythromycin is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
triazolam -
erythromycin
|
The macrolide increases the effect of the benzodiazepine
(source: Drug Bank
)
|
|
triazolam -
erythromycin
|
The macrolide increases the effect of the benzodiazepine
(source: Drug Bank
)
|
|
trimipramine -
erythromycin
|
Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
(source: Drug Bank
)
|
|
valproic acid -
erythromycin
|
The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Erythromycin is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
vardenafil -
erythromycin
|
Erythromycin may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil if Erythromycin is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
verapamil -
erythromycin
|
Erythromycin, a moderate CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of Verapamil if Erythromycin is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
vincristine -
erythromycin
|
Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Erythromycin is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
vinorelbine -
erythromycin
|
Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Erythromycin is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
voriconazole -
erythromycin
|
Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of erythromycin by decreasing its metabolism. Erythromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
vorinostat -
erythromycin
|
Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
(source: Drug Bank
)
|
|
zafirlukast -
erythromycin
|
Zafirlukast serum concentrations may be decreased by Erythromycin.
(source: Drug Bank
)
|
|
ziprasidone -
erythromycin
|
Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
(source: Drug Bank
)
|
|
zopiclone -
erythromycin
|
The macrolide antibiotic, erythromycin, may increase the serum concentration of zopiclone. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if erythromycin is initiated, discontinued or dose changed.
(source: Drug Bank
)
|
|
zuclopenthixol -
erythromycin
|
Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
(source: Drug Bank
)
|
